6879.Two
6879.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. 6879.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6879.TWO operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
6879.TWO maintains a strong liquidity position, with a current ratio of 9.27 and cash and equivalents amounting to TWD 250,687,000. The company's liquidity FPT (free cash flow to total liabilities) is supported by a healthy operating cash flow of TWD 151,330,000, although its free cash flow is negative at TWD -2,276,000. The company's debt-to-equity ratio is low at 0.01, indicating minimal leverage and a conservative capital structure.
In terms of profitability, 6879.TWO reports a return on equity (ROE) of 4.56% and a return on assets (ROA) of 4.01%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's net income of TWD 40,566,000 and operating income of TWD 20,931,000 reflect a solid but not exceptional performance in the current fiscal year.
The company's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where regulatory and pricing pressures can significantly impact revenue streams. The lack of geographic diversification may limit the company's ability to offset regional downturns with growth in other areas.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditure of TWD -417,000 indicates a minimal investment in new assets, which may suggest a focus on maintaining current operations rather than expanding. The company's outlook for the next fiscal year is neutral, with no major changes expected in its financial performance.
The risk assessment for 6879.TWO indicates a low risk of liquidity and dilution. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is conservative, with a low debt-to-equity ratio. The company's dilution potential is also low, with no significant dilution sources identified in recent filings. The company's conservative financial position and lack of dilution risks contribute to its overall stability.
Recent events, including filings and transcripts, have not indicated any material changes in the company's operations or financial position. The company's financial performance and risk profile remain consistent with its historical trends, and there are no significant new developments that would alter its current trajectory.
- 6879.TWO has a strong liquidity position with a current ratio of 9.27 and a low debt-to-equity ratio of 0.01.
- The company's return on equity and return on assets are below the industry median, indicating underperformance in capital efficiency.
- Revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification.
- The company is expected to maintain a stable revenue trajectory with no significant growth or decline projected.
- The risk assessment indicates a low risk of liquidity and dilution, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6879.TWO Market data — financials · 2026-05-27